157
Participants
Start Date
January 31, 2010
Primary Completion Date
April 30, 2011
Olodaterol (BI 1744)
Comparison of low and high dose on exercise endurance time in COPD patients
Olodaterol (BI 1744)
Comparison of low and high dose on exercise endurance time in COPD patients
Placebo
Comparison of low and high dose and placebo on exercise endurance time in COPD patients
Olodaterol (BI1744)
Comparison of low and high dose on exercise endurance time in COPD patients
Olodaterol (BI 1744) placebo
Placebo that represents olodaterol
1222.38.4380 Boehringer Ingelheim Investigational Site, Hallein
1222.38.4381 Boehringer Ingelheim Investigational Site, Leoben
1222.38.32004 Boehringer Ingelheim Investigational Site, Brussels
1222.38.32002 Boehringer Ingelheim Investigational Site, Edegem
1222.38.32001 Boehringer Ingelheim Investigational Site, Leuven
1222.38.32003 Boehringer Ingelheim Investigational Site, Liège
1222.38.1082 Boehringer Ingelheim Investigational Site, Vancouver
1222.38.1081 Boehringer Ingelheim Investigational Site, Hamilton
1222.38.1083 Boehringer Ingelheim Investigational Site, Toronto
1222.38.1080 Boehringer Ingelheim Investigational Site, Montreal
1222.38.4980 Boehringer Ingelheim Investigational Site, Berlin
1222.38.4985 Boehringer Ingelheim Investigational Site, Cologne
1222.38.4983 Boehringer Ingelheim Investigational Site, Dortmund
1222.38.4984 Boehringer Ingelheim Investigational Site, Großhansdorf
1222.38.4981 Boehringer Ingelheim Investigational Site, Kiel
1222.38.4986 Boehringer Ingelheim Investigational Site, Koblenz
1222.38.7080 Boehringer Ingelheim Investigational Site, Moscow
1222.38.7081 Boehringer Ingelheim Investigational Site, Moscow
1222.38.7082 Boehringer Ingelheim Investigational Site, Saint Petersburg
Lead Sponsor
Boehringer Ingelheim
INDUSTRY